Skip to content

Predictors of Cardiac Arrhythmia in Rheumatoid Arthritis Patients

Evaluation of QT Dispersion , P Wave Dispersion and Tp-e Dispersion as Predictors of Cardiac Arrhythmia in Rheumatoid Arthritis Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07782788
Enrollment
120
Registered
2026-08-24
Start date
2026-10-01
Completion date
2027-11-01
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis (RA)

Brief summary

To evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis and to assess their relationship with disease characteristics and inflammatory activity

Detailed description

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by persistent synovial inflammation and progressive joint destruction. In addition to musculoskeletal manifestations, patients with RA have an increased risk of cardiovascular morbidity and mortality compared with the general population. Cardiac arrhythmias represent one of the important cardiovascular complications in these patients and may contribute to sudden cardiac death Electrocardiographic markers reflecting abnormalities in atrial and ventricular depolarization and repolarization have gained increasing attention as predictors of arrhythmogenic risk. QT dispersion (QTd) reflects heterogeneity of ventricular repolarization and has been associated with ventricular arrhythmias. P-wave dispersion (PWD) represents inhomogeneous atrial conduction and is considered a predictor of atrial arrhythmias, particularly atrial fibrillation. Tp-e interval and Tp-e dispersion are relatively newer markers reflecting transmural dispersion of ventricular repolarization and have been linked to malignant ventricular arrhythmias Chronic inflammation, autonomic dysfunction, endothelial dysfunction and myocardial involvement in rheumatoid arthritis may contribute to abnormalities in these electrocardiographic parameters. Early identification of patients at higher risk of cardiac arrhythmias may improve risk stratification and allow timely intervention. Therefore, the present study aims to evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria * Age ≥18 years * Male and female patients

Exclusion criteria

* Presence of other autoimmune diseases * Thyroid disorders * Use of medications affecting cardiac conduction or repolarization such as amiodarone and other antiarrhythmic drugs * Electrolyte disturbances including hypocalcemia, hypokalemia and hypomagnesemia * Known cardiac diseases including ischemic heart disease, valvular heart disease, cardiomyopathy, heart failure or congenital heart disease

Design outcomes

Primary

MeasureTime frameDescription
QT dispersion, P-wave dispersion and Tp-e dispersionbaselineto assess QT dispersion , P wave dispersion and Tp-e dispersion on 12 lead ECG and compare their values between rheumatoid arthritis patients and healthy controls and to evaluate their association with the risk of cardiac arrhythmia

Secondary

MeasureTime frameDescription
Correlation between ECG parameters and disease activity assessed by DAS28at baselineto evaluate the correlation between QT dispersion P wave dispersion Tp-e dispersion with rheumatoid arthritis disease activity assessed by DAS28

Contacts

CONTACTkatreen N henin, master
Katrin.18313203@med.aun.edu.eg+2001553202412
PRINCIPAL_INVESTIGATORkatreen N henin, master

faculty of medicine , Assiut university ,Eygpt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026